This trial is for patients with early stage, low risk HER2+ BC. The objective is to see if zanidatamab is effective in treating the cancer, as determined by pathologic complete response.
1 Primary · 0 Secondary · Reporting Duration: through study completion, an average of 1 year
17 Total Participants · 1 Treatment Group
Primary Treatment: Zanidatamab · No Placebo Group · Phase 2
Age 18+ · Female Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: